FDA Alerts

The FDA has approved Xadago, an add-on treatment for patients with Parkinson disease who experience “off” episodes.

The FDA approved ribociclib, taken with an aromatase inhibitor, for the treatment of advanced or metastatic breast cancer in post-menopause women.

The FDA has approved Noctiva (desmopressin acetate) nasal spray for the treatment of frequent nighttime urination due to the overproduction of urine.

The US Food and Drug Administration has approved Odactra for the treatment of house dust mite-induced nasal inflammation.

The FDA has approved Xermelo to be used in combination with somatostatin analogue therapy for the treatment of carcinoid syndrome diarrhea.

The FDA has approved once-daily Qtern for the treatment of patients with type 2 diabetes, as an adjunct to diet and exercise for the improvement of glycemic control.

The FDA has approved Spiriva Respimat for long-term, once-daily maintenance treatment of asthma in individuals aged 6 and older.

The FDA approved the injection Siliq (brodalumab) to treat adults with moderate to severe plaque psoriasis.

The FDA has approved Emflaza (deflazacort) tablets and oral suspension for the treatment of patients aged 5 years and older with Duchenne muscular dystrophy.

The FDA approved Parsabiv (etelcalcetide) for the treatment of secondary hyperparathyroidism in adults with chronic kidney disease who are on hemodialysis.